Matrix Metalloproteinase-2 Conditions Human Dendritic Cells to Prime Inflammatory TH2 Cells via an IL-12- and OX40L-Dependent Pathway

Cancer Cell

Volumn 19, Issue 3, 2011, Pages 333-346

  Godefroy, Emmanuelle ^a   Manches, Olivier ^a   Dréno, Brigitte ^b   Hochman, Tsivia ^a   Rolnitzky, Linda ^a   Labarrière, Nathalie ^b   Guilloux, Yannick ^b   Goldberg, Judith ^a   Jotereau, Francine ^b   Bhardwaj, Nina ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b Team 12   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; INTERFERON RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 4; OX40 LIGAND; STAT1 PROTEIN; TRANSCRIPTION FACTOR GATA 3; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BASOPHIL; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LYMPHOCYTE DIFFERENTIATION; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 79952508760     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.01.037     Document Type: Article

References (52)

1. Botella-Estrada R., Escudero M., O'Connor J.E., Nagore E., Fenollosa B., Sanmartin O., Requena C., Guillen C. Cytokine production by peripheral lymphocytes in melanoma. Eur. Cytokine Netw. 2005, 16:47-55.
2. Brooks P.C., Stromblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85:683-693.
3. Brooks P.C., Silletti S., von Schalscha T.L., Friedlander M., Cheresh D.A. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998, 92:391-400.
4. Choi W.S., Jeon O.H., Kim H.H., Kim D.S. MMP-2 regulates human platelet activation by interacting with integrin alphaIIbbeta3. J. Thromb. Haemost. 2008, 6:517-523.
5. Coulie P.G., van der Bruggen P. T-cell responses of vaccinated cancer patients. Curr. Opin. Immunol. 2003, 15:131-137.
6. Decker T., Muller M., Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. 2005, 5:675-687.
7. Emonard H., Bellon G., Troeberg L., Berton A., Robinet A., Henriet P., Marbaix E., Kirkegaard K., Patthy L., Eeckhout Y., et al. Low density lipoprotein receptor-related protein mediates endocytic clearance of pro-MMP-2.TIMP-2 complex through a thrombospondin-independent mechanism. J. Biol. Chem. 2004, 279:54944-54951.
8. Everts B., Perona-Wright G., Smits H.H., Hokke C.H., van der Ham A.J., Fitzsimmons C.M., Doenhoff M.J., van der Bosch J., Mohrs K., Haas H., et al. Omega-1, a glycoprotein secreted by Schistosoma mansoni eggs, drives Th2 responses. J. Exp. Med. 2009, 206:1673-1680.
9. Falcone F.H., Dahinden C.A., Gibbs B.F., Noll T., Amon U., Hebestreit H., Abrahamsen O., Klaucke J., Schlaak M., Haas H. Human basophils release interleukin-4 after stimulation with Schistosoma mansoni egg antigen. Eur. J. Immunol. 1996, 26:1147-1155.
10. Gautier G., Humbert M., Deauvieau F., Scuiller M., Hiscott J., Bates E.E., Trinchieri G., Caux C., Garrone P. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 2005, 201:1435-1446.
11. Godefroy E., Moreau-Aubry A., Diez E., Dreno B., Jotereau F., Guilloux Y. alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen. J. Exp. Med. 2005, 202:61-72.
12. Godefroy E., Scotto L., Souleimanian N.E., Ritter G., Old L.J., Jotereau F., Valmori D., Ayyoub M. Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles. Clin. Immunol. 2006, 121:54-62.
13. Godefroy E., Wang Y., Souleimanian N.E., Scotto L., Stevanovic S., Chen Y.T., Valmori D., Ayyoub M. Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals. Cancer Immunol. Immunother. 2007, 56:1183-1192.
14. Grobe K., Becker W.M., Schlaak M., Petersen A. Grass group I allergens (beta-expansins) are novel, papain-related proteinases. Eur. J. Biochem. 1999, 263:33-40.
15. Hirohashi Y., Torigoe T., Inoda S., Kobayasi J., Nakatsugawa M., Mori T., Hara I., Sato N. The functioning antigens: beyond just as the immunological targets. Cancer Sci. 2009, 100:798-806.
16. Ito T., Wang Y.H., Duramad O., Hori T., Delespesse G.J., Watanabe N., Qin F.X., Yao Z., Cao W., Liu Y.J. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 2005, 202:1213-1223.
17. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58:1048-1051.
18. Jankovic D., Kullberg M.C., Noben-Trauth N., Caspar P., Paul W.E., Sher A. Single cell analysis reveals that IL-4 receptor/Stat6 signaling is not required for the in vivo or in vitro development of CD4+ lymphocytes with a Th2 cytokine profile. J. Immunol. 2000, 164:3047-3055.
19. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
20. Khammari A., Nguyen J.M., Pandolfino M.C., Quereux G., Brocard A., Bercegeay S., Cassidanius A., Lemarre P., Volteau C., Labarriere N., et al. Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol. Immunother. 2007, 56:1853-1860.
21. Kheradmand F., Kiss A., Xu J., Lee S.H., Kolattukudy P.E., Corry D.B. A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J. Immunol. 2002, 169:5904-5911.
22. Labarriere N., Pandolfino M.C., Gervois N., Khammari A., Tessier M.H., Dreno B., Jotereau F. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol. Immunother. 2002, 51:532-538.
23. Lauerova L., Dusek L., Simickova M., Kocak I., Vagundova M., Zaloudik J., Kovarik J. Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002, 49:159-166.
24. Liotta L.A., Tryggvason K., Garbisa S., Hart I., Foltz C.M., Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980, 284:67-68.
25. Liu Y.J. Thymic stromal lymphopoietin: master switch for allergic inflammation. J. Exp. Med. 2006, 203:269-273.
26. Liu Y.J., Soumelis V., Watanabe N., Ito T., Wang Y.H., Malefyt Rde W., Omori M., Zhou B., Ziegler S.F. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu. Rev. Immunol. 2007, 25:193-219.
27. Loose D., Van de Wiele C. The immune system and cancer. Cancer Biother. Radiopharm. 2009, 24:369-376.
28. McCarter M., Clarke J., Richter D., Wilson C. Melanoma skews dendritic cells to facilitate a T helper 2 profile. Surgery 2005, 138:321-328.
29. McKerrow J.H., Caffrey C., Kelly B., Loke P., Sajid M. Proteases in parasitic diseases. Annu. Rev. Pathol. 2006, 1:497-536.
30. Minkis K., Kavanagh D.G., Alter G., Bogunovic D., O'Neill D., Adams S., Pavlick A., Walker B.D., Brockman M.A., Gandhi R.T., et al. Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res. 2008, 68:9441-9450.
31. Moser M., Murphy K.M. Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. 2000, 1:199-205.
32. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1989, 7:145-173.
33. Nishimura T., Iwakabe K., Sekimoto M., Ohmi Y., Yahata T., Nakui M., Sato T., Habu S., Tashiro H., Sato M., et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 1999, 190:617-627.
34. Nishimura T., Nakui M., Sato M., Iwakabe K., Kitamura H., Sekimoto M., Ohta A., Koda T., Nishimura S. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol. 2000, 46(Suppl):S52-S61.
35. Ocmant A., Peignois Y., Mulier S., Hanssens L., Michils A., Schandene L. Flow cytometry for basophil activation markers: the measurement of CD203c up-regulation is as reliable as CD63 expression in the diagnosis of cat allergy. J. Immunol. Methods 2007, 320:40-48.
36. Oh K., Shen T., Le Gros G., Min B. Induction of Th2 type immunity in a mouse system reveals a novel immunoregulatory role of basophils. Blood 2007, 109:2921-2927.
37. Rosenberg S.A. Shedding light on immunotherapy for cancer. N. Engl. J. Med. 2004, 350:1461-1463.
38. Severa M., Remoli M.E., Giacomini E., Ragimbeau J., Lande R., Uze G., Pellegrini S., Coccia E.M. Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression. J. Leukoc. Biol. 2006, 79:1286-1294.
39. So T., Song J., Sugie K., Altman A., Croft M. Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment. Proc. Natl. Acad. Sci. USA 2006, 103:3740-3745.
40. Sokol C.L., Barton G.M., Farr A.G., Medzhitov R. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat. Immunol. 2008, 9:310-318.
41. Sokol C.L., Chu N.Q., Yu S., Nish S.A., Laufer T.M., Medzhitov R. Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat. Immunol. 2009, 10:713-720.
42. Soumelis V., Liu Y.J. Human thymic stromal lymphopoietin: a novel epithelial cell-derived cytokine and a potential key player in the induction of allergic inflammation. Springer Semin. Immunopathol. 2004, 25:325-333.
43. Soumelis V., Reche P.A., Kanzler H., Yuan W., Edward G., Homey B., Gilliet M., Ho S., Antonenko S., Lauerma A., et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 2002, 3:673-680.
44. Stefanidakis M., Bjorklund M., Ihanus E., Gahmberg C.G., Koivunen E. Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins. J. Biol. Chem. 2003, 278:34674-34684.
45. Steinfelder S., Andersen J.F., Cannons J.L., Feng C.G., Joshi M., Dwyer D., Caspar P., Schwartzberg P.L., Sher A., Jankovic D. The major component in schistosome eggs responsible for conditioning dendritic cells for Th2 polarization is a T2 ribonuclease (omega-1). J. Exp. Med. 2009, 206:1681-1690.
46. Swain S.L., Weinberg A.D., English M., Huston G. IL-4 directs the development of Th2-like helper effectors. J. Immunol. 1990, 145:3796-3806.
47. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100:655-669.
48. Tatsumi T., Kierstead L.S., Ranieri E., Gesualdo L., Schena F.P., Finke J.H., Bukowski R.M., Mueller-Berghaus J., Kirkwood J.M., Kwok W.W., et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J. Exp. Med. 2002, 196:619-628.
49. Watanabe N., Hanabuchi S., Soumelis V., Yuan W., Ho S., de Waal Malefyt R., Liu Y.J. Human thymic stromal lymphopoietin promotes dendritic cell-mediated CD4+ T cell homeostatic expansion. Nat. Immunol. 2004, 5:426-434.
50. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13:781-792.
51. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med. 2000, 192:1637-1644.
52. Yu Q., Sharma A., Oh S.Y., Moon H.G., Hossain M.Z., Salay T.M., Leeds K.E., Du H., Wu B., Waterman M.L., et al. T cell factor 1 initiates the T helper type 2 fate by inducing the transcription factor GATA-3 and repressing interferon-gamma. Nat. Immunol. 2009, 10:992-999.